Dr. Muthu's research interest is in the area of cognitive informatics, with a focus on the refinement and application of cognitive engineering methods to improve health information technology safety and augment clinical decision-making.
Dr. Furth's research focuses on defining risk factors for kidney disease progression in children; characterizing the effect of kidney function decline on neurodevelopment, cognitive abilities and behavior; identifying the prevalence and evolution of cardiovascular disease risk factors, and examining the effects of declining glomerular filtration rate on children’s growth.
Dr. DeMauro has special expertise in rigorous assessment of early childhood outcomes of high-risk neonates. Her research focuses on improving outcomes of children with bronchopulmonary dysplasia and school-age assessment of functional outcomes in preterm-born children.
Dr. Heuckeroth investigates mechanisms controlling bowel motility in order to find new ways to treat, diagnose, and prevent intestinal motility disorders. He works to define genetic, biochemical, and cellular processes that impact bowel function, with a special interest in the enteric nervous system and intestinal smooth muscle cells.
Dr. Olson aims to improve diagnostics and treatment of bone marrow failure (BMF) syndromes, and to improve clinical hematopoietic stem cell transplantation (HSCT) outcomes. He conducts clinical trials of HSCT for non-malignant hematologic diseases. His laboratory explores both basic and translational research focused on genomics of BMF and the impact of BMF on hematopoietic niche function during HSCT.
Dr. Schultz's research involves using magnetic resonance imaging to understand brain mechanisms and to create biomarkers that predict who has autism spectrum disorder (ASD), who will develop the disorder, and who will respond well to different interventions. More recently, he has developed a technology and innovation lab to exploit advances in perceptual computing, in order to develop more robust measurements of quantitative traits.
Dr. Lerman's research interests include non-infectious uveitis and temporomandibular (TMJ) arthritis. Her studies examine the utility of biologic agents to achieve, and maintain, uveitis control. Up to 80 percent of children with juvenile idiopathic arthritis (JIA) have potentially erosive TMJ arthritis, and she is exploring ways to best identify and monitor this often asymptomatic manifestation of JIA.
Dr. Psihogios' research focuses on improving treatment adherence in adolescents and young adults (AYA) with chronic medical conditions, particularly those with cancer. She uses real-time mobile health strategies to better understand the day-to-day factors that proximally impact treatment adherence.
Dr. Monos is an internationally recognized expert on histocompatibility (HLA) molecules. His work covers a wide spectrum of HLA-related issues that pertain to both the molecular (structure/function) aspects of HLAs, as well as the genetics of the major histocompatibility complex, that includes the genes encoding the HLA molecules.
Dr. Silverman studies the fundamental aspects of early-life commensal microbes that influence immune system development and function. He discovered that the MHC-II E molecule prevents type 1 diabetes by shaping the intestinal microbiota early in life.